about
Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina.Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer.Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes.Effects of an endothelin receptor antagonist on a model of hypertensive retinopathy.The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor.Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium.Development of primary human nasal epithelial cell cultures for the study of cystic fibrosis pathophysiologyCAMKII as a therapeutic target for growth factor-induced retinal and choroidal neovascularizationBioadhesive, non-drug-loaded nanoparticles as modulators of candidal adherence to buccal epithelial cells: a potentially novel prophylaxis for candidosisAbnormal Glycogen Storage by Retinal Neurons in DiabetesGlucocorticoids exert differential effects on the endothelium in an in vitro model of the blood-retinal barrierThe vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic
P50
Q35880995-2FAEA74E-76B6-4A6D-A912-5B67DF843C17Q37065040-2CEA463D-9A8D-45E8-9B54-26E7D52EC649Q39444571-136EBCDF-79E9-4688-87AD-4F210DA7E58AQ42767408-59B2FF0D-660E-4C74-9C0E-747E388BB290Q43261369-A8F23D67-25E6-4A99-A37C-E82F3EB40523Q44114910-8BA08287-D5A1-443E-A0C2-B6EA0744DC55Q45122703-BB836E92-A569-4A7A-A80E-4C480975EDC6Q46566361-D91666E0-130E-431A-ADFC-DF58E0FC2FBDQ57913593-BFF1272E-8E30-482A-8A01-0F42FC86EDDAQ64066407-5D33FF07-43F3-4236-BE50-19D852040B8CQ75326724-ED2D72E8-2927-41B0-B875-CD9289B09ADDQ86999445-341714E8-A06A-4CC5-8F93-A8C403B5A1F6Q91245378-4C52723E-95E5-499A-B015-CB71082198ECQ92400649-4B7FF62F-E944-46DD-B8D6-D1B026EB8174
P50
description
researcher
@en
name
Paul Canning
@en
Paul Canning
@nl
type
label
Paul Canning
@en
Paul Canning
@nl
prefLabel
Paul Canning
@en
Paul Canning
@nl
P106
P31
P496
0000-0002-0888-0124